Symptom dynamics during repeated serial allergen challenge chamber exposures to house dust mite: To the editor

Journal of Allergy and Clinical Immunology

Volumn 135, Issue 4, 2015, Pages 1071-1075

  Jacobs, Robert L ^a   Andrews, Charles P ^a   Ramirez, Daniel A ^a   Rather, Cynthia G ^a   Harper, Nathan ^b,c   Jimenez, Fabio ^b,c   Martinez, Hernan ^b,c   Manoharan, Muthu ^b,c   Carrillo, Andrew ^b,c   Gerardi, Margit ^b   Esch, Robert E ^e   He, Weijing ^b,c   Ahuja, Sunil K ^b,c,d  

^a Biogenics Research Chamber   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d University of Texas Health Science Center   (United States)

^e Greer Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HOUSE DUST ALLERGEN; ALLERGEN;

ALLERGEN CHALLENGE CHAMBER; ALLERGY; BRONCHOSPASM; CLINICAL TRIAL (TOPIC); DERMATOPHAGOIDES; DERMATOPHAGOIDES PTERONYSSINUS; ENVIRONMENTAL FACTOR; ENZYME LINKED IMMUNOSORBENT ASSAY; GENERAL DEVICE; HUMAN; LETTER; MILD INTERMITTENT ASTHMA; NATIONAL HEALTH ORGANIZATION; POLLINATION; PRIORITY JOURNAL; RHINOCONJUNCTIVITIS; RISK FACTOR; SEASON; SENSITIZATION; SYMPTOM; VISUAL ANALOG SCALE; ANIMAL; HYPERSENSITIVITY; IMMUNOLOGY; METHODOLOGY; PYROGLYPHIDAE; SYMPTOM ASSESSMENT;

ALLERGENS; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; HUMANS; HYPERSENSITIVITY; PYROGLYPHIDAE; RESEARCH DESIGN; SEASONS; SYMPTOM ASSESSMENT;

EID: 84926223196     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2014.09.047     Document Type: Article

References (15)

1. U.S. Food and Drug Administration Center for Biologics Evaluation and Research: Allergenic Products Advisory Committee, May 12, 2011. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/AllergenicProductsAdvisoryCommittee/UCM258587.pdf. Accessed May 28, 2014.
2. A. Togias Asthma, Allergy, and Inflammation Branch, Division of Allergy, Immunology and Transplantation, NIAID/NIH Environmental exposure units: clinical trial design for validation 2010 National Institute for Allergy and Infectious Diseases/National Institutes of Health Bethesda 1 12
3. J.A. Bernstein Correlation between a pollen challenge chamber and a natural allergen exposure study design for eliciting ocular and nasal symptoms: early evidence supporting a paradigm shift in drug investigation? J Allergy Clin Immunol 130 2012 128 129
4. P. Devillier, M. Le Gall, and F. Horak The allergen challenge chamber: a valuable tool for optimizing the clinical development of pollen immunotherapy Allergy 66 2011 163 169
5. R.L. Jacobs, N. Harper, W. He, C.P. Andrews, C.G. Rather, and D.A. Ramirez Responses to ragweed pollen in a pollen challenge chamber versus seasonal exposure identify allergic rhinoconjunctivitis endotypes J Allergy Clin Immunol 130 2012 122 127.e8
6. R.L. Jacobs, N. Harper, W. He, C.P. Andrews, C.G. Rather, and D.A. Ramirez Effect of confounding cofactors on responses to pollens during natural season versus pollen challenge chamber exposure J Allergy Clin Immunol 133 2014 1340 1346 e1-7
7. U. Bingel Avoiding nocebo effects to optimize treatment outcome JAMA 312 2014 693 694
8. G. de Vos Skin testing versus serum-specific IgE testing: which is better for diagnosing aeroallergen sensitization and predicting clinical allergy? Curr Allergy Asthma Rep 14 2014 430
9. F. Horak, J. Toth, B. Marks, U.P. Stubner, U.E. Berger, and S. Jager Efficacy and safety relative to placebo of an oral formulation of cetirizine and sustained-release pseudoephedrine in the management of nasal congestion Allergy 53 1998 849 856
10. G. Ciprandi, M.A. Tosca, and M. Silvestri The practical role of serum allergen-specific IgE as potential biomarker for predicting responder to allergen immunotherapy Expert Rev Clin Immunol 10 2014 321 324
11. M. Majori, M.L. Piccoli, R. Melej, V. Pileggi, and A. Pesci Lymphocyte activation markers in peripheral blood before and after natural exposure to allergen in asthmatic patients Respiration 64 1997 45 49
12. J.A. Woodfolk High-dose allergen exposure leads to tolerance Clin Rev Allergy Immunol 28 2005 43 58
13. L.Y. Liu, C.A. Swenson, E.A. Kelly, H. Kita, N.N. Jarjour, and W.W. Busse Comparison of the effects of repetitive low-dose and single-dose antigen challenge on airway inflammation J Allergy Clin Immunol 111 2003 818 825
14. P. Enck, U. Bingel, M. Schedlowski, and W. Rief The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov 12 2013 191 204
15. W.W. Busse, W.J. Morgan, P.J. Gergen, H.E. Mitchell, J.E. Gern, and A.H. Liu Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children N Engl J Med 364 2011 1005 1015